MediPharm Labs Australia Signs Supply and Manufacturing Agreement with Cannim Australia; Announces Plan to Launch New Over-the-Counter Products

TORONTO, March 08, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, is pleased to announce its wholly owned subsidiary, MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”), has entered into a new GMP white-label supply and contract manufacturing agreement with Cannim Australia Pty Ltd (“Cannim”). MediPharm Labs Australia will also provide Cannim with contract manufacturing with their starting material. “We are optimistic about our potential in 2021 for many good reasons including regulatory advancements,” said Keith Strachan, President and Interim CEO, MediPharm Labs. MediPharm Labs Australia was established in 2017. CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation.